European Medicines Agency

🚨 Alert: Beware of scams and phishing attempts! 🚨 We have been made aware of fraudulent activities where illegal third parties are using our name, emails, logo, and even staff names to request money through fake documents. 🔍 Stay Vigilant: Watch out for fake invoices, emails, or phone calls impersonating EMA and asking for money transfers. EMA will never ask for payments from citizens. 💡 Our Role: EMA is responsible for the scientific evaluation of new medicines in the EU and monitoring the safety of those already on the market. Most of our interactions with companies and citizens are often linked to these regulatory procedures. 📢 Report Scams: If you encounter any such scam attempts, please report them to your national authorities responsible for crimes and cybercrime. Stay safe and informed! #EMA #ScamAlert #StaySafe #Pharmaceuticals #EU

EMA is pleased to host the second Veterinary Innovation Day – a two-day event dedicated to innovation in veterinary medicines.  We're bringing together experts to discuss how the EU legislative framework supports innovation and how new medicines can reach the market more efficiently while maintaining high standards of safety and efficacy. 📅 13-14 March | 🏛️ European Medicines Agency 📢 Register now! ✔️ In-person attendance: Express your interest by 3 March 2025. ✔️ Virtual attendance: Pre-register by 13 March 2025. Find out more and register here 👉 https://lnkd.in/dPK9Bay6 #VetInnovation #AnimalHealth #VeterinaryMedicines #Innovation

📺 Watch our new video to discover how data from real-world healthcare settings can help patients access safer and more effective medicines faster. Data Analysis and Real World Interrogation Network #DARWINEU is celebrating its 3rd anniversary. From Estonia to Spain, DARWIN EU data partners generate real-world evidence that helps European regulators address knowledge gaps and better understand the use, safety and benefits of medicines. Today, the network has: ✅ 30 data partners, including healthcare data from primary care, hospitals, registries, and biobanks. ✅ Access to data from 160 million patients in 16 countries. ✅ 58 completed or ongoing studies since 2022. For example, we’ve studied the patterns of opioid use, such as morphine, to help avoid overprescription and misuse and examined antibiotic prescriptions in the EU to help tackle antibiotic resistance. #HealthData

The European medicines regulatory network’s vision for clinical evidence by 2030 has just been published! This scientific article describes 6 guiding principles for generating excellent clinical evidence: 🔹 Every step of clinical evidence generation will be further guided by the patient voice; 🔹 Existing data and knowledge will further inform generation of clinical evidence; 🔹 Study design will be driven by research questions; 🔹 Clinical trials will be more efficient and impactful; 🔹 Real-world evidence will be enabled and its value fully established; 🔹 Trust will be built through transparency. We welcome all actors to apply these principles for excellent clinical evidence. Since we know that our followers may have questions and interesting views, we want to facilitate a discussion opportunity on this topic. We plan a new LinkedIn Live session in April, where our experts will dive deeper into what these principles mean. Follow our posts for more information.

Fake medicines traded are on the rise in the EU. This phenomenon includes medicines in high demand. 📈 ⚠️ If a medicine is prescription only, and your doctor doesn’t prescribe it to you, don’t just go online and try to get it anyway. This makes you vulnerable to fall for falsified medicines. Beware that when you buy medicines from unauthorised websites you are at greater risk of purchasing fakes.    Are you a wholesale distributor or a broker? 🔎 You can find on EMA's website practical recommendations on how to spot suspicious offers and what to do in such situation: https://lnkd.in/enawsxXR Fake medicines have a damaging impact on public health - let's all be vigilant. 📺 https://lnkd.in/eKyEhAXE   #EUvsFakeMedicines

🌱 EMA Achieves EMAS Certification: A Milestone in Sustainability We were certified with the EU Eco-Management and Audit Scheme (EMAS), marking a key step in our ongoing commitment to environmental sustainability. This certification reflects our dedication to reducing our environmental footprint, promoting sustainability, and engaging stakeholders in meaningful environmental actions. At EMA, we strive to be a climate-friendly and resource-efficient organisation, empowering staff through initiatives like our Green Group and ensuring compliance with EU environmental legislation. In short, we’re committed to protecting the environment for future generations. 🌍   Find out more in the article below 👇 https://lnkd.in/efBi67Fv #Sustainability #EMAS #EMA #EnvironmentalResponsibility #GreenLeadership #ClimateAction #EU #SustainableFuture

Our safety committee, the #PRAC, at its February meeting carried out its broad range of responsibilities, which cover all aspects of the risk management of the use of medicines: assessment of safety signals, risk management plans, periodic safety update reports and post-authorisation safety studies. 📄 Information on all topics discussed by the PRAC is available in the agenda. Read more 👉 https://lnkd.in/eHVhb_Kr #SafeMedicines #PublicHealth

Yesterday we had the pleasure to welcome the new Commissioner for Health and Animal Welfare, Olivér Várhelyi, to Amsterdam. A first meeting between the Commissioner and our Executive Director, Emer Cooke, took place in Brussels on 6 February, when they had initial discussions on the importance of close cooperation with EMA. During the yesterday's visit, Commissioner Várhelyi presented his priorities to EMA’s leadership team, as well as to all EMA's staff. The Commissioner highlighted his work on the: ✔️ Critical Medicines Act ✔️ revision of the pharmaceutical legislation aiming to futureproof and increase regulatory efficiencies ✔️ upcoming Biotech Act ✔️ targeted evaluation of the legislation on medical devices and in vitro diagnostics. We at EMA are looking forward to our ongoing collaboration with Commissioner Várhelyi. We are ready to support him and the Directorate-General for Health and Food Safety to help achieve the European Commission’s ambitions for the benefit of public and animal health. EU Health and Food Safety

🌍💡 Celebrating International Day of Women and Girls in Science!   Today, we honour the vital role of women and girls in scientific innovation. At EMA, we're proud to highlight the journeys of inspiring women who are shaping the future of science.   This day serves as a reminder of how far we've come and how much more we can achieve. By encouraging women in science, technology, engineering, and mathematics (STEM), and fostering inclusive representation, we continue to challenge outdated gender stereotypes and create pathways for future generations to thrive in these fields.    Meet three inspiring women at EMA whose journeys began as young girls with a passion for science and who continue to pave the way for others in the field 👇   #WomenInScience #GirlsInSTEM #ScienceForAll #STEMCareers    Giulia Gabrielli Maria Mavris Agnès Maillet

EMA has established a regular procedure for manufacturers to request scientific advice on the intended clinical development strategy for high-risk medical devices. The advice procedure is available for two types of medical devices: ✅ class III devices – invasive and sustain or support human life ✅ class IIb active devices - intended to administer or remove medicines. Are you a manufacturer? Submit your request now! 🔗 Click the link for more information: https://lnkd.in/e6bJ-n9V